Inscription Capital LLC Acquires 3,827 Shares of Charles River Laboratories International, Inc. $CRL

Inscription Capital LLC increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 185.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,896 shares of the medical research company’s stock after acquiring an additional 3,827 shares during the quarter. Inscription Capital LLC’s holdings in Charles River Laboratories International were worth $922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Cromwell Holdings LLC increased its stake in shares of Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 152 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Charles River Laboratories International in the 2nd quarter worth approximately $29,000. Geneos Wealth Management Inc. increased its position in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. Allworth Financial LP raised its stake in Charles River Laboratories International by 172.7% during the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after buying an additional 190 shares during the last quarter. Finally, SJS Investment Consulting Inc. bought a new stake in Charles River Laboratories International in the third quarter worth $48,000. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a report on Monday, December 15th. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Mizuho set a $215.00 target price on shares of Charles River Laboratories International in a research note on Friday, January 9th. Argus set a $200.00 price target on shares of Charles River Laboratories International in a report on Monday, November 17th. Finally, Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $209.46.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $218.13 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The company has a 50 day moving average price of $193.71 and a 200-day moving average price of $175.13. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $228.88. The firm has a market capitalization of $10.74 billion, a PE ratio of -139.83, a P/E/G ratio of 6.57 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. During the same quarter last year, the company posted $2.59 earnings per share. The firm’s quarterly revenue was down .5% on a year-over-year basis. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.